NASDAQ
2.65USD
-0.09 (-3.28%)
We have scored 10 news catalysts on Insight Molecular Diagnostics Inc. (IMDX) over the past 12 months. The biggest single-day move next to one of them came Aug 11, 2026, when IMDX closed −7.1%: “Oncocyte Q2 Earnings Call Highlights”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
86.7M
P/E
—
EPS
—
Beta
1.86
52W range
2.42-8.51
Day range
2.61–2.88
Open
2.85
Prev close
2.74
Volume
154.1K
Avg volume
227.7K
Dividend
0.00
IPO
2015-12-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Insight Molecular Diagnostics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Insight Molecular Diagnostics Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for IMDX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Insight Molecular Diagnostics Inc. functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, Insight Molecular Diagnostics provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. Insight Molecular Diagnostics was founded in 2009 and maintains its principal office in Irvine, California.
